Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...

Treatment with Emgality reduced monthly migraine headache days by 4.1 days. Eli Lilly has announced that in its recent CONQUER trial, Emgality (galcanezumab-gnlm) met the primary and all key secondary ...